<DOC>
	<DOCNO>NCT00167765</DOCNO>
	<brief_summary>The purpose prospective , randomize , double blind , placebo-controlled multicenter pilot study evaluate effectiveness abciximab rescue hypoperfused brain tissue , assess MRI , relative safety abciximab patient wake-up stroke .</brief_summary>
	<brief_title>Abciximab Wake-up Stroke</brief_title>
	<detailed_description>Intravenous ( IV ) administration recombinant tissue plasminogen activator ( rt-PA ) approve therapy patient acute ischemic stroke present within 3 hour symptom onset . Approximately 17-30 % ischemic stroke find awaken . Since stroke onset determine patient awake stroke , de facto ineligible thrombolytic therapy . Nevertheless , possible patient suffer stroke within hour prior become awake , may thus good candidate thrombolysis . Combined diffusion- ( DWI ) perfusion- ( PWI ) weight MR imaging ( MRI ) able identify hypoperfused still viable brain tissue , potentially salvageable ischemic penumbra ( PWI-DWI mismatch ) . A recent study examine 34 patient wake-up stroke median National Institute Health Stroke Scale ( NIHSS ) score 13 ( range 6 22 ) DWI PWI . The author find 73 % patient present non-lacunar stroke within 3 hour wake sleep PWI-DWI mismatch large hypoperfused area . This image pattern may associate potential benefit thrombolysis beyond current 3-hour window . Induced spontaneous reperfusion brain area initial PWI hypoperfusion associate reduced infarction favourable clinical outcome . A phase IIa placebo-controlled safety pilot efficacy trial abciximab patient acute ischemic stroke treat within 24 hour symptom onset find abciximab cause symptomatic intracranial hemorrhage show trend toward high rate patient minimal residual disability1 . Thus , abciximab may attractive therapy option patient wake-up stroke PWI-DWI mismatch . The purpose prospective , randomize , double blind , placebo-controlled multicenter pilot study evaluate effectiveness abciximab rescue hypoperfused brain tissue , assess MRI , relative safety abciximab patient wake-up stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patient awakes acute ischemic stroke anterior circulation . Planned start study agent &gt; 3 hour £6 hour time awaken &lt; 1 hour MRI mismatch diagnosis establish ( cf . item 5 ) . Prerandomization NIHSS score 420 . Age &gt; 18 year . MRI show PWIDWI mismatch define visual estimation , PWI lesion &gt; 130 % DWI volume . Written informed consent , sign date subject ( subject ’ authorize representative , allow local law ) person obtain consent , indicate agreement comply protocolspecified procedure . General : Participation another study investigational drug device within last 30 day . Prior participation present study , plan participation another trial . Symptoms suggestive subarachnoid hemorrhage , even MRI/CT scan negative hemorrhage . Women know pregnant , lactating , positive indeterminate pregnancy test . Stroke Related Stupor coma ( NIHSS level consciousness score ≥2 { item 1a } ) . High clinical suspicion septic embolus . Rapidly improve symptom . Thrombosis involve cerebral vein . Brain Imaging Related Evidence ICH T2* MRI and/or noncontrast enhanced head CT. MRI and/or CT evidence nonvascular cause neurological symptom . DWI infarct size &gt; 50 % MCA territory . Signs mass effect cause shift midline structure CT scan . Contraindication undergo MR imaging ( eg pacemaker ) . Suspicion occlusion ipsilateral ICA MRA . Safety Related Persistent hypertension systolic blood pressure ( SBP ) &gt; 185 mm Hg diastolic blood pressure ( DBP ) &gt; 110 mm Hg ( mean 3 consecutive arm cuff reading 2030 minute ) , control antihypertensive therapy require nitroprusside control . Anticipated need major surgery within 72 hour randomization ( eg , carotid endarterectomy , hip fracture repair ) . Any intracranial surgery , serious head trauma ( head injury require hospitalization ) , stroke within past 3 month . History ICH time past . Major trauma time stroke ( eg , hip fracture ) . Presence history intracranial neoplasm arteriovenous malformation . Intracranial aneurysm , unless surgically treat &gt; 3 month . Major hemorrhage past 21 day . Major surgery , serious trauma , lumbar puncture , arterial puncture noncompressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplant . For unlisted procedure , operate surgeon consult assess risk Presumed document history vasculitis . Known systemic bleeding disorder ( eg , von Willebrand ’ disease , hemophilia , others ) . Platelet count &lt; 100'000 cells/µL . Congenital acquire coagulopathy ( eg , secondary anticoagulant ) cause either follow : A . Activated partial thromboplastin time ( aPTT ) prolongation great 2 second upper limit normal local laboratory , except due isolated factor XII deficiency . The use protamine sulfate reverse heparin effect allow . B . International normalized ratio ( INR ) ³1.4 . Subjects receive warfarin prior entry eligible provide INR &lt; 1.4 warfarin safely discontinue least 3648 h. Potentially Interfering Outcome Assessment Prestroke Barthel Index ( BI ) &lt; 95 modified Rankin scale score ( mRS ) &gt; 1 . Life expectancy &lt; 3 month . Other serious illness ( eg , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment ) . Drug Related Treatment rtPA , Ancrod , intraarterial thrombolytic qualify stroke administration intraarterial systemic thrombolytic therapy last 7 day . Treatment rtPA indicate commercially available , judgment investigator patient , risk/benefit ratio acceptable treatment rtPA . Need antiplatelet agent ( eg , aspirin , ticlopidine , clopidogrel , dipyridamole ) , unfractionated low molecular weight heparin , direct thrombin inhibitor , Factor Xa inhibitor , oral anticoagulant , NSAID ( exclude COX2 inhibitor ) post studyagent head CT scan . Treatment aspirin prior randomization exclusion criterion . Allergy hypersensitivity reaction ( include anaphylaxis ) clinically significant reaction ( include thrombocytopenia ) administration abciximab murine protein , know . Treatment unfractionated low molecular weight heparin , direct thrombin inhibitor , Factor Xa inhibitor within 48 hour randomization , irrespective aPTT result heparin dose receive ( exception minimal heparin use maintain open IV infusion line , &lt; 100 units/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stroke , ischemic</keyword>
	<keyword>acute ischemic stroke</keyword>
</DOC>